Skip to content
Delayed ~15 min

URGN UROGEN PHARMA

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: not announced yet

What 12 analyst firms say about UROGEN PHARMA: their latest ratings, price targets and how far the stock is from them. How it works

24.75 USD−0.98 (−3.81%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+115.7%to the avg target 53.38 USD+28.63 USD
Buy 9 · Hold 2 · Sell 0

11 rated views · 12 analyst/firm records · 12 firms

Latest report19 Oct 2026avg report date 16 Jul
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8072
  • Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8050

Recent analyst activity · last 90 days

Our tracked history has 4 reports on URGN from 4 analyst firms in the last 90 days (12 firms in the past year).

Comparing each firm's latest target with its previous one: 2 left it unchanged.

No firm's latest available rating differs from its previous one.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
D Boral CapitalJason KolbertBuy31 Mar 202633.00 USD
Goldman SachsPaul K ChoiHold30 Apr 202648.00 USD
GuggenheimMichael SchmidtBuy6 Aug 202658.00 USD
H.C. WainwrightRaghuram SelvarajuBuy19 Oct 202675.00 USD
JefferiesAmin MakaremBuy10 Sep 202656.00 USD
Ladenburg ThalmannKevin M DegeeterBuy11 May 2026Conflicting reports · excluded
OppenheimerLeland GershellBuy28 Oct 2026—
Piper SandlerKelsey GoodwinBuy5 Aug 202658.00 USD
TD CowenTara BancroftBuy5 Aug 202660.00 USD
UBSUnnamed analystBuy9 Jul 2026—
Weiss RatingsUnnamed analyst—15 Oct 2026—
Data feed RESEARCHResearch TeamHold15 Jun 202639.00 USD

Partial coverage · checked 6 Nov (6 Nov 2026, 02:55 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.